Allogene Therapeutics (ALLO)
(Delayed Data from NSDQ)
$2.50 USD
+0.04 (1.63%)
Updated May 31, 2024 04:00 PM ET
After-Market: $2.49 -0.01 (-0.40%) 4:22 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Allogene Therapeutics, Inc. [ALLO]
Reports for Purchase
Showing records 61 - 80 ( 213 total )
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pivotal ALPHA2 Trial to Start Mid-2022; 1Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pivotal ALLO-501A Trial Starting Mid-2022; 2021 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q21: Two Registration Trials to Begin in 2022 Pending FDA Discussion
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Looking into 1Q22, Cash Balance, & Price Target Changes
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology-Looking into 1Q22, Cash Balance, & Price Target Changes
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FDA Lifts Clinical Holds on AlloCAR-T Programs; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department